• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期 EGFR 阳性鼻咽癌诱导化疗序贯同期放化疗联合靶向治疗的疗效临床观察研究:预测模型构建与疗效验证。

Clinical observational study on the efficacy of induction chemotherapy sequential concurrent radiotherapy combined with targeted therapy in patients with locally advanced EGFR-positive nasopharyngeal carcinoma: prediction model construction and efficacy testing.

机构信息

Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.

North Sichuan Medical College, Nanchong, 637000, China.

出版信息

Eur Arch Otorhinolaryngol. 2023 Dec;280(12):5409-5416. doi: 10.1007/s00405-023-08157-9. Epub 2023 Aug 2.

DOI:10.1007/s00405-023-08157-9
PMID:37530857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10620248/
Abstract

OBJECTIVE

To establish a nomogram for prediction of prognosis in EGFR-positive advanced nasopharyngeal carcinoma (NPC) patients who were treated with induction chemotherapy (IC) and concurrent chemoradiotherapy (CCRT). The clinical data of 124 NPC patients who received IC sequential CCRT combined with targeted therapy at the Department of Oncology of the Affiliated Hospital of North Sichuan Medical College between June 2017 and September 2022 were retrospectively reviewed. Logistic regression analysis was used to identify the prognostic factors for building the nomogram.

RESULTS

Multifactorial regression analysis showed that the use of targeted drugs and T stage were independent factors of prognosis (p < 0.05) and the equation Y = 0.476 + 2.733X1 + - 0.758 × 2 (Y = efficacy, X1 = targeted drug therapy, X2 = T stage) was obtained. Then, a prognostic nomogram prediction model was constructed. The prediction model was validated internally for 1000 times using the Bootstrap resampling method with an accuracy of 79.29%. The calibration curve suggests that the predicted values fit well with the true values. The clinical decision curve (DCA) shows that the model has good clinical predictive value.

CONCLUSION

The use of targeted therapy significantly improved the prognosis of patients with EGFR-positive advanced NPC. For advanced NPC patients with T1 and T2 stages, IC sequenced with CCRT is more effective, and the addition of targeted therapy can further improve patients' prognosis. For advanced NPC patients with T3 and T4 stages, IC sequenced with CCRT is ineffective, and the addition of targeted therapy can significantly improve patient prognosis.

摘要

目的

建立一个列线图,用于预测接受诱导化疗(IC)和同期放化疗(CCRT)的表皮生长因子受体(EGFR)阳性晚期鼻咽癌(NPC)患者的预后。回顾性分析 2017 年 6 月至 2022 年 9 月在川北医学院附属医院肿瘤科接受 IC 序贯 CCRT 联合靶向治疗的 124 例 NPC 患者的临床资料。采用 logistic 回归分析确定建立列线图的预后因素。

结果

多因素回归分析显示,靶向药物的使用和 T 分期是独立的预后因素(p<0.05),并得出方程 Y=0.476+2.733X1-0.758×2(Y=疗效,X1=靶向药物治疗,X2=T 分期)。然后,构建了一个预后列线图预测模型。使用 Bootstrap 重采样方法对该预测模型进行了 1000 次内部验证,准确率为 79.29%。校准曲线表明预测值与真实值拟合良好。临床决策曲线(DCA)表明该模型具有良好的临床预测价值。

结论

靶向治疗显著改善了 EGFR 阳性晚期 NPC 患者的预后。对于 T1 和 T2 期的晚期 NPC 患者,IC 序贯 CCRT 更有效,联合靶向治疗可进一步提高患者的预后。对于 T3 和 T4 期的晚期 NPC 患者,IC 序贯 CCRT 无效,联合靶向治疗可显著改善患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/d38e1b5b5a32/405_2023_8157_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/684d5ee2a752/405_2023_8157_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/26f7c4a4053f/405_2023_8157_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/3b5a6efd31c8/405_2023_8157_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/d38e1b5b5a32/405_2023_8157_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/684d5ee2a752/405_2023_8157_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/26f7c4a4053f/405_2023_8157_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/3b5a6efd31c8/405_2023_8157_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f44e/10620248/d38e1b5b5a32/405_2023_8157_Fig4_HTML.jpg

相似文献

1
Clinical observational study on the efficacy of induction chemotherapy sequential concurrent radiotherapy combined with targeted therapy in patients with locally advanced EGFR-positive nasopharyngeal carcinoma: prediction model construction and efficacy testing.局部晚期 EGFR 阳性鼻咽癌诱导化疗序贯同期放化疗联合靶向治疗的疗效临床观察研究:预测模型构建与疗效验证。
Eur Arch Otorhinolaryngol. 2023 Dec;280(12):5409-5416. doi: 10.1007/s00405-023-08157-9. Epub 2023 Aug 2.
2
Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.局部晚期鼻咽癌诱导化疗联合放化疗与单纯诱导化疗联合放疗的配对分析:一项多中心研究
Oncotarget. 2017 Feb 21;8(8):14078-14088. doi: 10.18632/oncotarget.13285.
3
Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.诱导化疗及同期放化疗后辅助化疗/维持化疗在局部晚期鼻咽癌患者中的疗效:两个中心的经验。
Cancer Med. 2023 Mar;12(6):6811-6824. doi: 10.1002/cam4.5470. Epub 2022 Nov 24.
4
Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.局部晚期鼻咽癌诱导化疗加 IMRT 与诱导化疗加基于 IMRT 的同期放化疗的回顾性队列研究。
J Cancer Res Clin Oncol. 2019 Jul;145(7):1857-1864. doi: 10.1007/s00432-019-02925-z. Epub 2019 May 6.
5
Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.诱导化疗联合同期放化疗与单纯诱导化疗联合容积旋转调强放疗治疗 II-IVB 期鼻咽癌患者的回顾性对照研究。
Radiat Oncol. 2018 Aug 13;13(1):148. doi: 10.1186/s13014-018-1092-0.
6
The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis.诱导化疗或辅助化疗联合同期放化疗对 T3-4N0-1M0 期鼻咽癌的疗效:倾向评分匹配分析。
Cancer Biol Ther. 2023 Dec 31;24(1):2274121. doi: 10.1080/15384047.2023.2274121. Epub 2023 Nov 15.
7
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.多西他赛、顺铂和氟尿嘧啶诱导化疗后序贯同步放化疗或单纯放化疗用于局部晚期非地方性鼻咽癌
Oral Oncol. 2016 Nov;62:114-121. doi: 10.1016/j.oraloncology.2016.10.011. Epub 2016 Oct 22.
8
MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.基于 MRI 的放射组学比较诱导化疗联合同期放化疗与同期放化疗联合辅助化疗对局部晚期鼻咽癌的生存获益:一项多中心研究。
Radiother Oncol. 2022 Jun;171:107-113. doi: 10.1016/j.radonc.2022.04.017. Epub 2022 Apr 21.
9
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.诱导化疗后同期放化疗与单纯同期放化疗治疗局部晚期鼻咽癌:III 期多中心随机对照临床试验的长期结果。
Eur J Cancer. 2019 Sep;119:87-96. doi: 10.1016/j.ejca.2019.07.007. Epub 2019 Aug 16.
10
Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.诱导多西他赛、铂类和氟尿嘧啶化疗对接受同步放化疗的III期或IVA/B期鼻咽癌患者的影响:两项平行的2期临床试验的最终结果
Cancer. 2017 Jun 15;123(12):2258-2267. doi: 10.1002/cncr.30566. Epub 2017 Feb 13.

本文引用的文献

1
Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study.局部区域放疗对初治转移性鼻咽癌的疗效:一项真实世界研究。
Transl Oncol. 2021 Nov;14(11):101187. doi: 10.1016/j.tranon.2021.101187. Epub 2021 Aug 5.
2
Identification of an autophagy-related prognostic signature in head and neck squamous cell carcinoma.鉴定头颈部鳞状细胞癌中的自噬相关预后特征。
J Oral Pathol Med. 2021 Nov;50(10):1040-1049. doi: 10.1111/jop.13231. Epub 2021 Aug 18.
3
Nasopharyngeal carcinoma: an evolving paradigm.
鼻咽癌:一个不断发展的范例。
Nat Rev Clin Oncol. 2021 Nov;18(11):679-695. doi: 10.1038/s41571-021-00524-x. Epub 2021 Jun 30.
4
Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.非流行地区与同步转移性鼻咽癌患者生存相关的转移特征。
Oral Oncol. 2021 Apr;115:105200. doi: 10.1016/j.oraloncology.2021.105200. Epub 2021 Feb 19.
5
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.《CSCO/ASCO 鼻咽癌临床诊疗指南》:放化疗用于局部晚期鼻咽癌的根治性治疗
J Clin Oncol. 2021 Mar 1;39(7):840-859. doi: 10.1200/JCO.20.03237. Epub 2021 Jan 6.
6
Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma.鼻咽癌靶向治疗的研究进展主要基于信号通路。
Signal Transduct Target Ther. 2020 Oct 23;5(1):245. doi: 10.1038/s41392-020-00340-2.
7
Anti-EGFR therapies in nasopharyngeal carcinoma.鼻咽癌的抗 EGFR 治疗。
Biomed Pharmacother. 2020 Nov;131:110649. doi: 10.1016/j.biopha.2020.110649. Epub 2020 Aug 21.
8
The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis.调强放疗联合或不联合尼妥珠单抗治疗 III-IVb 期鼻咽癌患者的长期生存:倾向评分匹配分析。
BMC Cancer. 2019 Nov 19;19(1):1122. doi: 10.1186/s12885-019-6156-5.
9
Current Perspectives on Nasopharyngeal Carcinoma.鼻咽癌的研究现状。
Adv Exp Med Biol. 2019;1164:11-34. doi: 10.1007/978-3-030-22254-3_2.
10
Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives.《鼻咽癌诊断与治疗中国专家共识:基于当前实践的证据及未来展望》
Cancer Manag Res. 2019 Jul 10;11:6365-6376. doi: 10.2147/CMAR.S197544. eCollection 2019.